Streetbeat News

Products Services

ARM

UBS has initiated coverage on Arm Holdings PLC with a 'Buy' rating, citing strong growth opportunities driven by AI expansion. Arm's increasing market share in PCs and data centers, along with solid returns on R&D investments, are key factors in this positive outlook.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

CUK

Cunard's Queen Mary 2 hosted a neuroscience study showing that slow travel at sea can enhance cognitive abilities by 26% in just five days. The research highlights benefits in memory, spatial reasoning, logical thinking, and problem-solving.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

SNOW

Snowflake's stock rose by 3% after Wedbush upgraded it, highlighting its advantageous position to benefit from the increasing demand for AI products.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

BABA

The article discusses the author's decision to reduce exposure to Alibaba while maintaining a positive outlook. Key highlights include strong performance in Taobao and Tmall, Alibaba Cloud's growth driven by AI services, and significant growth in the AIDC segment.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

TGEN

Tecogen Inc. has received orders for 12 cogeneration systems for buildings in the Northeast, highlighting its strong project developer relationships.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

CME

CME Group has completed the conversion of 28-day TIIE interest rate swaps to F-TIIE overnight index swaps, enhancing liquidity in the Mexican derivatives market. This shift aligns with global best practices by moving to a risk-free rate based on overnight repo transactions.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

JYNT

Centric Brands has formed a strategic joint venture with Preston Konrad to expand the Preston Lane lifestyle brand. This partnership aims to leverage Centric Brands' expertise in brand development and distribution to enhance Preston Lane's market reach.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

AMLX

Amylyx Pharmaceuticals reported positive phase 2 results for AMX0035 in Wolfram Syndrome, with a potential phase 3 trial in 2025. An interim analysis for Progressive Supranuclear Palsy is expected in mid-2025. The company has $234.4 million in cash, funding operations into 2026, but may need additional funds in 2025.

Portfolio Pulse from

November 25, 2024 | 8:00 pm

TEM

Tempus AI has acquired Ambry Genetics, which will expand its testing portfolio and redefine precision medicine. This acquisition is expected to enhance Tempus AI's capabilities in the field of genetic testing and precision medicine.

Portfolio Pulse from

November 25, 2024 | 7:45 pm

CLX

Clorox (CLX) stock has reached a 52-week high, driven by recovery, improved distribution, and a focus on innovation and expansion despite inflation and cost challenges.

Portfolio Pulse from

November 25, 2024 | 7:15 pm